Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035351 | 0.91 | TGFBR1 (0.61) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4033819 | 0.88 | TGFBR1 (0.59) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4032898 | 0.80 | TGFBR1 (0.55) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL15849494 | 0.79 | TGFBR1 (0.62) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4037908 | 0.79 | TGFBR1 (0.56) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4033864 | 0.76 | TGFBR1 (0.82) | TGFBR1MAPK14RIPK2ACVR1BMEN1 | |
| SCHEMBL4039041 | 0.75 | TGFBR1 (0.53) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5695773 | 0.75 | CD274 (0.58) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5695754 | 0.75 | TGFBR1 (0.59) | TGFBR1MAPK14SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4030943 | 0.75 | TGFBR1 (0.57) | TGFBR1MAPK14RIPK2ACVR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | claimed |
| JP-2006527720-A | — | — | 2006-12-07 | — | — | JP | claimed |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | claimed |
| EP-1660494-A2 | THIAZOLES AS INHIBITORS OF THE ALK-5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2004111046-A2 | THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | claimed |
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1660494-A2 | THIAZOLES AS INHIBITORS OF THE ALK-5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2004111046-A2 | THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885MAPK14 319/4885RIPK2 650/4885 |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMAD3, ALK, SMAD2 | TGFBR1 4/4885MAPK14 386/4885RIPK2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.